Fairmount Funds Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $48.4M | Buy |
3,459,913
+14,100
| +0.4% | +$197K | 6.27% | 9 |
|
|
2025
Q1 | $46.4M | Hold |
3,445,813
| – | – | 7.21% | 7 |
|
|
2024
Q4 | $66.1M | Hold |
3,445,813
| – | – | 6.57% | 7 |
|
|
2024
Q3 | $78.4M | Buy |
3,445,813
+1,600,000
| +87% | +$36.4M | 6.36% | 8 |
|
|
2024
Q2 | $24M | Hold |
1,845,813
| – | – | 2.71% | 11 |
|
|
2024
Q1 | $32.3M | Buy |
1,845,813
+476,190
| +35% | +$8.34M | 3.52% | 8 |
|
|
2023
Q4 | $29.8M | Hold |
1,369,623
| – | – | 3.15% | 8 |
|
|
2023
Q3 | $21M | Hold |
1,369,623
| – | – | 2.53% | 14 |
|
|
2023
Q2 | $32.6M | Hold |
1,369,623
| – | – | 4.59% | 7 |
|
|
2023
Q1 | $34.8M | Hold |
1,369,623
| – | – | 5.99% | 6 |
|
|
2022
Q4 | $40M | Hold |
1,369,623
| – | – | 6.35% | 5 |
|
|
2022
Q3 | $28.1M | Buy |
1,369,623
+425,531
| +45% | +$8.73M | 4.94% | 8 |
|
|
2022
Q2 | $10.9M | Hold |
944,092
| – | – | 2.5% | 15 |
|
|
2022
Q1 | $17.5M | Hold |
944,092
| – | – | 4.13% | 11 |
|
|
2021
Q4 | $18.7M | Hold |
944,092
| – | – | 6.15% | 6 |
|
|
2021
Q3 | $15.5M | Buy |
944,092
+909,000
| +2,590% | +$15M | 5.65% | 8 |
|
|
2021
Q2 | $642K | Hold |
35,092
| – | – | 0.26% | 18 |
|
|
2021
Q1 | $581K | Hold |
35,092
| – | – | 0.24% | 19 |
|
|
2020
Q4 | $554K | Buy |
+35,092
| New | +$554K | 0.2% | 18 |
|